3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Leukemia, Myeloid, Acute
24
Breast Neoplasms
15
Sarcoma
9
Myelodysplastic Syndromes
9
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Multiple Myeloma
7
Leukemia, Myelomonocytic, Chronic
7
Myeloproliferative Disorders
6
Uterine Cervical Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Prostatic Neoplasms
4
Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Leukemia, Monocytic, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Hepatocellular
4
Biliary Tract Neoplasms
4
Advanced Solid Tumour
4
Stomatitis
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Neuroendocrine Tumors
3
Mucositis
3
Leukemia, Myelomonocytic, Acute
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Interventions
Cisplatin
18
Specimen Handling
10
Radiotherapy
10
Cetuximab
10
Magnetic Resonance Spectroscopy
9
Radiotherapy, Intensity-Modulated
8
Carboplatin
7
1,2-diaminocyclohexaneplatinum II citrate
7
pembrolizumab
6
Platinum
6
Paclitaxel
5
Drug Therapy
5
Celecoxib
5
cemiplimab
4
X-Rays
4
Surgical Procedures, Operative
4
Radiation
4
Fluorouracil
4
Biopsy
4
Taxes
3
Standard of Care
3
Docetaxel
3
durvalumab
2
Radiotherapy, Image-Guided
2
RRx-001
2
Practice Guidelines as Topic
2
Observation
2
Nivolumab
2
Injections
2
Fenretinide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Mouth Neoplasms
×
Injections
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts